Prog. Biophy. Mol. Biol., 70, 73-94
(1998).
2. Yong, V.W., et al., Matrix metalloproteinases and
diseases of the CNS. Trends in Neuroscience, 21,
75-80 (1998).
3. Kähäri, V.M., and Saarialho-Kere
2900
Caribbean See Central America
Central America +50 2 2410-2300
Chile +56 2 3400 000
China +86 21 3222 4788
Colombia +57 1 425 4770
Ecuador +593 2 2981677
Guatemala See Central America
Hong Kong +852
2900
Caribbean See Central America
Central America +50 2 2277 2222
Chile +56 2 3400 000
China +86 21 3222 4788
Colombia +57 1 425 4770
Ecuador +593 2 2981677
Guatemala See Central America
Hong Kong +852
some undissolved particulate solids may be observed.
Experimental: 75 µL of a 10 mg/mL solution of antibody is dissolved in 425 µL PBS (phosphate buffer
saline, pH = 7.4). 100 µL of this antibody solution
Int. J. Peptide Protein Res., 43, 431.
5. R. von Eggelkraut-Gottanka, et al. (2003) ChemBioChem, 4, 425.
6. M. Keller & A. D. Miller (2001) Bioorg. Med. Chem. Lett., 11, 857.
7. P. White, et al. (2004) J
to Vaccines
and Therapeutic Protein Production. PDA J.
Pharmaceut. Sci. Technol. 64(5) 2010: 419–
425. •
Brice Madeline (upstream process
engineer at Valneva SE) and
corresponding author Sylvain Ribaud
38843 (2001).
74. Kaeberlein, M., et al., J. Biol. Chem., 280, 17038-17045 (2005).
75. Howitz, K.T., et al., Nature, 425, 191-196 (2003).
Te
ch
n
ic
a
l
A
rt
ic
le
Antibiot., 23,
425-427 (1970).
28. Beynon, R.J., and Salvesen, G.S., “Commercially
available proteinase inhibitors”, Appendix III from
Proteolytic Enzymes: A Practical Approach (2
nd
edition
. 554000 50 µg
Ref.: Alexandrov, K., et al. 1998. FEBS Lett. 425, 460; Casey, P.J., and Seabra, M.C. 1996. J.
Biol. Chem. 271, 5289.
REP-2, His•Tag®, Human, Recomb., Spodoptera frugiperda
Binds to a